Trial Outcomes & Findings for Rapid Acceleration for Diagnostics in Underserved Populations: Home Testing (NCT NCT04949243)

NCT ID: NCT04949243

Last Updated: 2023-09-22

Results Overview

Number of participants who reported at their first follow-up assessment as having close contact (within 6 feet) with people who do not live with them.

Recruitment status

COMPLETED

Target enrollment

338 participants

Primary outcome timeframe

2 weeks

Results posted on

2023-09-22

Participant Flow

The project team utilized a robust communications campaign and mobilized community partners to assist with outreach and to organize COVID-19 (SARs-CoV-2) antigen testing kit distribution events. Community members received tests via online order (distributed by Amazon), and in person at local distribution centers and events.

Participant milestones

Participant milestones
Measure
People Who Use the Self Administered SARs-CoV-2 Antigen Testing Kits
The observational sub-study was open to the general population of targeted counties, and embedded within the larger public health intervention that distributed at-home, self-administered COVID tests. The sub-study looked at potential socio-behavioral mechanisms of SARS-CoV-2 Community Transmission: social interactions, health behaviors, healthcare utilization, knowledge, disease burden, feasibility of at-home testing.
Overall Study
STARTED
338
Overall Study
COMPLETED
263
Overall Study
NOT COMPLETED
75

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Rapid Acceleration for Diagnostics in Underserved Populations: Home Testing

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
People Who Use the Self Administered SARs-CoV-2 Antigen Testing Kits
n=338 Participants
The observational sub-study was open to the general population of targeted counties, and embedded within the larger public health intervention that distributed at-home, self-administered COVID tests. The sub-study looked at potential socio-behavioral mechanisms of SARS-CoV-2 Community Transmission: social interactions, health behaviors, healthcare utilization, knowledge, disease burden, feasibility of at-home testing.
Age, Continuous
47.10 years
STANDARD_DEVIATION 14.37 • n=99 Participants
Sex/Gender, Customized
Sex · Female
226 Participants
n=99 Participants
Sex/Gender, Customized
Sex · Male
88 Participants
n=99 Participants
Sex/Gender, Customized
Sex · Not Indicated
24 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
16 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
295 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
27 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
3 Participants
n=99 Participants
Race (NIH/OMB)
Asian
6 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
34 Participants
n=99 Participants
Race (NIH/OMB)
White
252 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
13 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
30 Participants
n=99 Participants
Region of Enrollment
United States
338 Participants
n=99 Participants

PRIMARY outcome

Timeframe: 2 weeks

Population: Data not collected on 116 participants.

Number of participants who reported at their first follow-up assessment as having close contact (within 6 feet) with people who do not live with them.

Outcome measures

Outcome measures
Measure
People Who Use the Self Administered SARs-CoV-2 Antigen Testing Kits
n=222 Participants
The observational sub-study was open to the general population of targeted counties, and embedded within the larger public health intervention that distributed at-home, self-administered COVID tests. The sub-study looked at potential socio-behavioral mechanisms of SARS-CoV-2 Community Transmission: social interactions, health behaviors, healthcare utilization, knowledge, disease burden, feasibility of at-home testing.
Number of Participants Who Reported Not Following Social Distancing Guidelines
164 Participants

SECONDARY outcome

Timeframe: 2 weeks

Population: Data not collected on 114 participants.

Number of participants who reported at their first follow-up assessment as having avoided public spaces, gatherings, or crowds as a prevention measure.

Outcome measures

Outcome measures
Measure
People Who Use the Self Administered SARs-CoV-2 Antigen Testing Kits
n=224 Participants
The observational sub-study was open to the general population of targeted counties, and embedded within the larger public health intervention that distributed at-home, self-administered COVID tests. The sub-study looked at potential socio-behavioral mechanisms of SARS-CoV-2 Community Transmission: social interactions, health behaviors, healthcare utilization, knowledge, disease burden, feasibility of at-home testing.
Number of Participants That Avoided Public Spaces, Gatherings, or Crowds as a Prevention Measure
84 Participants

SECONDARY outcome

Timeframe: 4 months

Population: Data not collected.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 4 months

Outcome measures

Outcome measures
Measure
People Who Use the Self Administered SARs-CoV-2 Antigen Testing Kits
n=338 Participants
The observational sub-study was open to the general population of targeted counties, and embedded within the larger public health intervention that distributed at-home, self-administered COVID tests. The sub-study looked at potential socio-behavioral mechanisms of SARS-CoV-2 Community Transmission: social interactions, health behaviors, healthcare utilization, knowledge, disease burden, feasibility of at-home testing.
Number of Participants With Positive SARs-CoV-2 Antigen Test Results
7 Participants

SECONDARY outcome

Timeframe: 4 months

Population: Data not collected.

Outcome measures

Outcome data not reported

Adverse Events

People Who Use the Self Administered SARs-CoV-2 Antigen Testing Kits

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Saira Siddiqui, MPH

Duke University

Phone: 919-688-8464

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place